Home >
AEPSO Argentina launches digital map to find people with psoriasis in the country
2015/04/09 - News from patients associations
Psoriasis, recognised today by the World Health Organization (WHO) as a painful and incapacitating non communicable chronic disease, affects more than 800 000 Argentineans. AEPSO (Asociación Civil para el Enfermo de Psoriasis) celebrates its 10th anniversary raising awareness and supporting the rights of the patients. In order to better know what is going on with the disease in Argentina and to reach out the different communities, AEPSO has launched an interactive digital map, accessible through Facebook, that aims to identify and connect all psoriasis patients in each corner of the country.
Silvia Fernández Barrio, president and founder of AEPSO, has acknowledged that social networks have contributed to show unknown realities that they wish to work on for the benefit of the patients: “This is why this map came about, a tool that will give precise information where persons with psoriasis in Argentina live, and thus better help each one of them, guide them to informed professionals and to centres where they can get the treatment they need, as well as to create ties among patients going through the same experience in their community. In a territory as vast and with different realities we have to take advantage of technology as an opportunity to shorten distance and time”.
During the next 10 years, Beatriz Larrea, Executive Director of AEPSO, said that “we would like to achieve a presence of groups of people with psoriasis in every region of the country. That there are patients gathering, giving their time and sharing their experiences and knowledge in order to help others to better cope with their reality”.
One of the greatest obstacles that a psoriasis patients still faces is ignorance. There are patients that do not see a doctor because of the old prejudice that this is a disease that there is nothing you can do, so they give up. “Nothing could be farther from the truth”, exclaimed Silvia Fernández Barrio, adding “those people we must reach them through AEPSO; so that they know who we are, that we are here to help them, guide them, provide them with information and suggest where they can start to treat themselves. Their life can change, and is going to change”.
“We strive to achieve that no patient across the country lives withouth diagnosis or treatment; we have a lot of work ahead of us, but we know this is the way”, added the president of AEPSO.
You can find the map at:
https://www.facebook.com/pages/AEPSO/103448854973?sk=app_1497274527196166
SPIN Presentation
Recent news
- 2019/04/18 Focus on...
- 2019/04/17 Focus on...
- 2018/07/16 Focus on...
- 2018/07/09 Focus on...
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Moderate-to-severe psoriasis and pregnancy: impact on fertility, pregnancy outcome and treatment perspectives.
G Ital Dermatol Venereol.
2019 Jun , 154, (3):305-314.
Psoriasis affects 2-4% of the world's population, with no difference between men and women and 70% of patients experiencing disease onset before the age of 40, which coincides with the reproductive years. Few data are available from literature on impact of psoriasis on fertility, course and outcome of pregnancy and risk associated with treatments. Recent studies on other immune-mediated inflammatory diseases, among which psoriasis is also included, indicate that rheumatoid arthritis and (...)
see on pubmed
Squamous cell carcinoma-related antigen 2 level is a reliable indicator of severe psoriasis involving the face.
G Ital Dermatol Venereol.
2019 Jun , 154, (3):374-375.
Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis.
J. Cell. Physiol..
2019 Jul , 234, (7):9943-9955.
Dimethyl fumarate (DMF) is an important oral treatment option for various autoimmune diseases, such as multiple sclerosis (MS) and psoriasis. DMF and its dynamic metabolite, monomethyl fumarate (MMF) are the major compounds that exert therapeutic effects on several pathologic conditions in part, through downregulation of immune responses. The exact mechanism of DMF is yet to be fully understood even though its beneficial effects on the immune system are extensively studied. It has been (...)
see on pubmed
on Atopic Dermatitis
Silver nanoparticles assessment in moisturizing creams by ultrasound assisted extraction followed by sp-ICP-MS.
Talanta.
2019 May 15, 197:530-538.
Advances on nanometrology require reliable sample pre-treatment methods for extracting/isolating nanomaterials from complex samples. The current development deals with a discontinuous ultrasonication (60% amplitude, 15 cycles of ultrasound treatment for 59 s plus relaxing stage for 59 s, 20 mL of methanol) method for a fast and quantitative extraction of silver nanoparticles (Ag NPs) from moisturizing creams. Possibilities offered by modern inductively coupled plasma mass spectrometry (ICP-MS) (...)
see on pubmed
Should we treat every infant with a probiotic?
Underwood MA.
Should we treat every infant with a probiotic?
Minerva Pediatr..
2019 Jun , 71, (3):253-262.
Intestinal dysbiosis is associated with a long list of both acute and chronic inflammatory diseases and appears to be increasing in developed countries over the last century with the introduction of antibiotics, changes in sanitation, formula feeding and cesarean sections. The evidence supporting prophylactic administration of probiotic microbes to very preterm infants for the prevention of necrotizing enterocolitis, late onset sepsis and death is strong. The evidence for benefit of (...)
see on pubmed
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
Choi EJ et al.
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
J Enzyme Inhib Med Chem.
2019 Dec , 34, (1):613-619.
This study aimed to evaluate the effects of cinnamamides on atopic dermatitis (AD) and the mechanisms underlying these effects. To this end, the actions of two cinnamamides, (E)-3-(4-hydroxyphenyl)-N-phenylethyl acrylamide (NCT) and N-trans-coumaroyltyramine (NCPA), were determined on AD by orally administering them to mice. Oral administration of the cinnamamides ameliorated the increase in epidermal and dermal thickness as well as mast cell infiltration. Cinnamamides suppressed serum (...)
see on pubmed
